Trevena Revenue 2012-2021 | TRVN

Trevena revenue from 2012 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Trevena Annual Revenue
(Millions of US $)
2020 $3
2019 $0
2018 $6
2017 $
2016 $4
2015 $6
2014 $
2013 $0
2012 $1
2011 $2
Trevena Quarterly Revenue
(Millions of US $)
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $3
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31 $0
2018-09-30 $3
2018-06-30 $3
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30 $2
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $2
2015-03-31 $1
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30 $0
2013-03-31 $0
2012-12-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.188B $0.003B
Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00